TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

Search

CSL Ltd

Closed

SectorIndustrials

257.01 0.65

Overview

Share price change

24h

Current

Min

250.43

Max

257.24

Key metrics

By Trading Economics

Income

1.3B

2B

Sales

1.5B

8.2B

P/E

Sector Avg

28.972

33.198

EPS

1.831

Dividend yield

1.7

Profit margin

24.437

Employees

32,698

EBITDA

1.5B

3.2B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+26.05% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.70%

2.54%

Next Dividend date

9 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-14B

121B

Previous open

256.36

Previous close

257.01

News Sentiment

By Acuity

34%

66%

121 / 468 Ranking in Industrials

CSL Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 lut 2025, 21:55 UTC

Earnings

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 lut 2025, 21:34 UTC

Earnings

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 sie 2024, 23:23 UTC

Earnings

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 sie 2024, 22:49 UTC

Earnings

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 mar 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 lut 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 lut 2025, 21:40 UTC

Earnings

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 lut 2025, 21:19 UTC

Earnings

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 lut 2025, 21:13 UTC

Earnings

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 lut 2025, 21:12 UTC

Earnings

CSL Interim Dividend US$1.30/Security

10 lut 2025, 21:12 UTC

Earnings

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 lut 2025, 21:11 UTC

Earnings

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 lis 2024, 03:53 UTC

Market Talk

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 paź 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 paź 2024, 22:20 UTC

Market Talk

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 sie 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 sie 2024, 22:34 UTC

Earnings

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 sie 2024, 22:18 UTC

Earnings

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 sie 2024, 22:18 UTC

Earnings

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 sie 2024, 22:17 UTC

Earnings

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 sie 2024, 22:16 UTC

Earnings

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 sie 2024, 22:15 UTC

Earnings

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 sie 2024, 22:14 UTC

Earnings

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 sie 2024, 22:13 UTC

Earnings

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 sie 2024, 22:13 UTC

Earnings

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 sie 2024, 22:11 UTC

Earnings

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 sie 2024, 22:10 UTC

Earnings

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 sie 2024, 22:09 UTC

Earnings

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 sie 2024, 22:08 UTC

Earnings

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 sie 2024, 22:07 UTC

Earnings

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Peer Comparison

Price change

CSL Ltd Forecast

Price Target

By TipRanks

26.05% upside

12 Months Forecast

Average 317.092 AUD  26.05%

High 360.3 AUD

Low 250 AUD

Based on 14 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

12

Buy

2

Hold

0

Sell

Sentiment

By Acuity

121 / 468 Ranking in Industrials

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.